BD Onclarity™
HPV Assay
Extend the
power of HPV
testing
While preventable,
cervical cancer takes a heavy toll
The WHO has set a clear goal to eliminate cervical cancer, and all countries have committed to it. This goal can be achieved through a comprehensive approach with vaccination, screening and treatment.1
The BD Onclarity™ HPV Assay provides extended genotyping, by simultaneously detecting 14 high-risk genotypes*, with individual results for 6 genotypes.2
*BD Onclarity™ HPV Assay detects the 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 classified as carcinogenic, 68 classified as probably carcinogenic, and 66 classified as possibly carcinogenic to humans.2,3
Know the HPV type, understand the risk
Not all high-risk HPV types are the same
Persistent infections increase risk; know the history
Detecting adenacarcinoma essential
4vHPV, quadrivalent HPV vaccine; 9vHPV, nonavalent HPV vaccine; ASCCP, American Society for Colposcopy and Cervical Pathology; CIN, cervical intraepithelial neoplasia; CIN1, cervical intraepithelial neoplasia grade 1; CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial neoplasia grade 3; FDA, Food and Drug Administration; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; PCR, polymerase chain reaction.
1. World Health Organization. Human papillomavirus (HPV) and cervical cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer Last updated 5 March 2024. Accessed May 31, 2024.
2. BD OnclarityTM HPV Assay European Product information, 8089899(14). Updated November 2020.
3. Human Papillomavirus and Related Diseases Report, WORLD. Version posted at www.hpvcentre.net on 10 March 2023. table 29, p. 155. https://hpvcentre.net/statistics/reports/XWX.pdf?t=1717150168919, accessed on May 30, 2024.
4. Li N et al. Int J Cancer. 2011;128:927-935.
5. de Sanjose S et al. Lancet Oncol. 2010;11:1048-1056.
6. Bottari F et al. J Clin Microbiol. 2015;53:2109-2114.
7. Stoler MH et al. Gynecol Oncol. 2019,153(1):26-33.
8. Schiffman M et al. Int J Cancer. 2016;139(11):2606-2615.
9. Elfgren K et al. Am J Obstet Gynecol 2017;216(3):264.e1-7.
10. Adegoke O et al. J Womens Health. 2012;21(10):1031-1037.
11. Kyrgiou M et al. Br J Cancer. 2020;123(4):510-517.
12. Katki HA et al. Lancet Oncol. 2011;12(7):663-672.
13. Vaughan LM and Malinowski DP. Rev Bras Ginecol Obstet. 2019;41(5):357-359.